Market Research Report
Global Pre-filled Syringes Market - 2019-2026
|Published by||DataM Intelligence||Product code||760533|
Delivery time: 1-2 business days
|Global Pre-filled Syringes Market - 2019-2026|
|Published: November 1, 2019||Content info:||
Global Pre-filled Syringes Market is expected to grow at a CAGR of XX% to reach market value of USD XXXX million by 2025.
Pre-filled syringes are the readily available syringes with drug components to be administered. Prefilled syringes are being used to deliver drug categories such as vaccines, therapeutic proteins, blood stimulants, erythroproteins and more. The key issues related to parenteral drug delivery such as lack of convenience, affordability, lack accuracy in drug volume, sterility, safety, etc. are overcome by prefilled syringes. Prefilled syringes edge on traditional parentral drugs over contamination issues, thus these are used across wide array of therapeutic sector
Global Pre-filled Syringes Market 2016-2025, in USD Million
The global pre-filled syringe market is propelled by multiple factors such as technological advancements, the high prevalence of chronic diseases and disorders, and growing adoption of self-injection devices. One of the major reasons for the rapid growth of prefilled syringe technology is its suitability for home use, a prevalent healthcare trend that provides the benefit of convenience for regular patients. Pen injectors and auto-injectors are common for self-administered insulin injections and other hormone replacement therapies which are also used in the home-based treatment of major therapeutic areas like autoimmune disease, cancer, and allergies. Moreover, the reduction in amount of active pharmaceutical ingredient (API) used by pre-filled syringes would reduce the cost of pre-filled syringe manufacturing and will help the manufacturers to achieve sustainable growth in production of pre-filled syringe products.
Product recalls, high manufacturing cost, limited manufacturing facility are such factors which are expected to the hinder the market over the forecast period. Further, the surge in Biosimilars in pharmaceuticals market and increasing availability of injectable drugs in pre-filled form would provide a lucrative opportunities to the market.
The global pre-filled syringe market is segmented as material type, by design, and by application. The material type segment, is classified into Glass-based and Plastic-based pre-filled syringes. By design, the market is segmented into single-chamber prefilled syringes, dual-chamber prefilled syringes, and customized prefilled syringes. Further, by application the global pre-filled syringe market is categorized into anaphylaxis, rheumatoid arthritis, diabetes, and others.
The majority of the prefilled syringes are made out of glass. However, the adoption of plastic-based cyclopoly olefin (COP) resin is driving the growth of plastic based pre-filled syringe market over the forecast period. This resin are becoming more common due to the material's improved break resistance, as well as its decreased surface reactivity and drug absorption rates compared to glass. Japan is one of the leading country in plastic based pre-filled syringes market. The country has more than 50% of the pre-filled syringes in plastic form.
The global pre-filled syringe market is segmented as North America, Europe, Asia-Pacific, South America, and Rest of the World. Europe dominated the prefilled syringe market in 2017 and it is expected to grow in the forecast period. High adoption of patient safety measures and the presence of key companies are the factors responsible for the growth of Europe Prefilled Syringe Market. However, North America is expected to witness the fastest growth in regional market owing to rapid adoption of pre-filled syringes for multiple drugs in 2017.
Market share of Global Pre-filled Syringes Market by Region, 2017
North America 35.32%
Asia Pacific 11.03%
South America 4.24%
Rest of the World 9.70%
Major players in the prefilled syringes market are focused on expanding their product range with technologically advanced products. This in turn will help the companies to increase their supply and marketing capacity sustain the market pressure. In July 2015, Vetter launched Vetter-Ject, a closure system which is suitable for the filling of highly sensitive drug components. Likewise, in April 2015, SCHOTT introduced a new polymer prefillable syringe design-SCHOTT TopPac. The design is aimed at refining the safety and stability of sensitive drugs.
The new product launch is the key strategy adopted by the market leaders to improve their market presence and grab a major share of the market.
For instance, Novartis, in September 2018, received FDA approval for their Xolair (omalizumab) prefilled syringe. The pre-filled syringe drug is approved for allergic asthma and chronic idiopathic urticaria indications. Similarly, W. L. Gore & Associates, Inc. ("Gore) plans to commercially launch the GORE ImproJect Plunger for Pre-Filled Syringes by 2018